Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN057 in Hemophilia A or B
NCT06747416Phase 2Not yet recruiting
- Sponsor
- Alphamab Oncology
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of Armocibart in hemophilia A, hemophilia B (HB), sponsored by Alphamab Oncology. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Armocibart
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT06747416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747416.